Vera Therapeutics Inc. (VERA)
Market Closed
17 Jul, 20:00
NASDAQ (NMS) NASDAQ (NMS) Primary $
38. 50
-0.62
-1.5849%
$
3.1B Market Cap
- P/E Ratio
- Div Yield
1.39M Volume
-2.16 Eps
$ 39.12
Previous Close 
Want to track VERA and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Vera Therapeutics' Atacicept Shows Sustained, Substantial Improvement In Kidney Function For Patients At Almost Two Years
On Saturday, Vera Therapeutics Inc. VERA released data from its ORIGIN Phase 2b trial of atacicept in immunoglobulin A nephropathy (IgAN), which showed stabilized kidney function through 96 weeks of long-term follow-up.
Benzinga | 1 year ago
Vera: Potential First Of Atacicept As A B-Cell Modulator For IgAN Patients
Vera Therapeutics, Inc. topline 36-week data from the phase 3 ORIGIN study, using Atacicept for the treatment of patients with IgA Nephropathy, expected Q2 of 2025. 96-week data from the phase 2 ORIGIN study, using Atacicept for the treatment of patients with IgA Nephropathy, expected at ASN Kidney week oral presentation October 23–27 2024. The global IgA Nephropathy market is expected to reach $41.24 billion by 2033.
Seekingalpha | 1 year ago
